Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone Acetonide for Upper Eyelid Retraction in Thyroid Eye Disease
NCT07471997Completed
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
- Start
- Jun 2024
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of triamcinolone in thyroid eye disease (TED), sponsored by Instituto de Oftalmología Fundación Conde de Valenciana. Primary endpoint: Margin Reflex Distance 1 at 1 month. Started Jun 2024; status: completed.
02
Drugs
triamcinolone
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07471997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07471997.